Connect with us

News

Why These Couples Are Glad They Delayed Their Weddings – Inside Edition

Published

on

News

CDC tells adults to get booster shot amid omicron concerns

Published

on

Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky gives her opening statement during the Senate Health, Education, Labor and Pensions hearing on “Next Steps: The Road Ahead for the COVID-19 Response” on Capitol Hill in Washington, November 4, 2021.

Elizabeth Frantz | Reuters

The Centers for Disease Control and Prevention on Monday strengthened its recommendation on Covid booster shots, telling all adults that they “should” get an additional dose amid growing concern about the newly identified omicron variant.

“The recent emergence of the Omicron variant (B.1.1.529) further emphasizes the importance of vaccination, boosters, and prevention efforts needed to protect against COVID-19,” CDC Director Dr. Rochelle Walensky said in a statement Monday.

The CDC cleared booster doses for all adults earlier this month, saying everyone over 18 “may” get a shot if they wanted one. Only people 50 and over were told they “should” get the shots at the time. The agency is now giving its strongest recommendation for everyone 18 and older, saying they should get an additional shot six months after their initial Pfizer or Moderna series, or two months after their first Johnson & Johnson shot.

The World Health Organization, in a paper published Sunday, warned that global risk posed by omicron is “very high.” The variant has more than 30 mutations on its spike protein alone, some of which are associated with higher transmission and reduced antibody protection. The WHO said these mutations could fuel future surges of infection with “severe consequences.”

“Early data from South Africa suggest increased transmissibility of the Omicron variant, and scientists in the United States and around the world are urgently examining vaccine effectiveness related to this variant,” Walensky said.

Though omicron is believed to be more infectious than the predominant delta variant, it is not yet clear how much the heavily mutated strain will affect the strength of currently available vaccines. Moderna and Pfizer said they will have more data on this in about two weeks. The companies maintain that they can adjust their vaccines relatively quickly to combat new variants.

“I don’t think that the result will be the vaccines don’t protect,” Pfizer CEO Albert Bourla told CNBC’s “Squawk Box” on Monday. “I think the result could be, which we don’t know yet, the vaccines protect less.”

Bourla said that Pfizer can develop a new vaccine within 100 days. Moderna CEO Stephane Bancel told CNBC on Monday that the company could deploy a higher-dosage booster shot against omicron quickly but a variant-specific vaccine could take months.

Though omicron has not yet been detected in the U.S., President Joe Biden on Monday said the country will face the variant sooner or later, and encouraged Americans to get booster shots for added protection. Walensky, in her Monday statement, urged people to get tested as well.

“I also want to encourage people to get a COVID-19 test if they are sick,” Walensky said. “Increased testing will help us identify Omicron quickly.”

The emergence of omicron comes as public health officials are already concerned about a winter Covid surge and declining vaccine strength.

A study published in the journal Science this month found that the Pfizer vaccine’s efficacy at preventing infection declined from 86% to 43% from February to October. Moderna’s vaccine dropped from 89% to 58%, and J&J’s vaccine fell from 86% to 13% efficacy against infection in the same study.

However, Pfizer found that its booster dose provides 95% protection against symptomatic infection in a clinical trial of 10,000 people.

Continue Reading

News

New Blood Video Shows Michael C. Hall & Cast Answering Dexter Trivia – Screen Rant

Published

on

New Blood Video Shows Michael C. Hall & Cast Answering Dexter Trivia  Screen Rant

Continue Reading

News

Dow Jones Futures: Stock Market Surges As Biden Rules Out Lockdowns; 4 EV Stocks Race Higher

Published

on

Dow Jones futures were higher late Monday. The stock market bounced after Friday’s omicron Covid-19 sell-off, as President Joe Biden ruled out new lockdowns. Electric-vehicle stocks Li Auto, Lucid Motors, Rivian and Tesla raced higher Monday.




X



On Monday, the Dow Jones Industrial Average moved up 0.7%. The S&P 500 rose 1.3%, while the Nasdaq led the way, rising 1.9%. Crude oil prices rose over 2%. Bitcoin surged 7%. And the 10-year Treasury yield climbed to 1.53%.

Among the Dow Jones leaders, Apple (AAPL) traded up 2.2%, while Microsoft (MSFT) moved up 2.1% in today’s stock market. Nike (NKE) remains below a recent buy point despite a 1.1% gain Monday.

Electric-vehicle leader Tesla (TSLA) rallied 5.1% Monday. EV peer Rivian (RIVN) surged nearly 7%, while Lucid Motors (LCID) gained 6.5%. Chinese EV leader Li Auto (LI) bolted higher after delivering earnings, while Xpeng Motors (XPEV) edged higher.

Among the top stocks to buy and watch, Nucor (NUE), Pioneer Natural Resources (PXD), Pfizer (PFE) and Zim Integrated Shipping (ZIM) are near new buy zones.

Microsoft, Nucor and Tesla are IBD Leaderboard stocks. Apple was featured in this week’s Stocks Near A Buy Zone story. And Zim was spotlighted in last week’s IPO Leaders story.

Dow Jones Futures Today: Biden Comments On Omicron; Powell, Yellen On Deck

After the stock market close Monday, Dow Jones futures, along with S&P 500 futures and Nasdaq 100 futures, were up 0.2% vs. fair value. Remember that trading in Dow Jones futures and elsewhere doesn’t necessarily translate into actual trading in the next regular stock market session.

Among exchange traded funds, Innovator IBD 50 (FFTY) moved up 1.6% Monday. Nasdaq 100 tracker Invesco QQQ Trust (QQQ) gained 2.2%. And the SPDR S&P 500 ETF (SPY) ascended 1.2%.

U.S. Stock Market Today Overview

Index Symbol Price Gain/Loss % Change
Dow Jones (0DJIA) 35135.78 +236.44 +0.68
S&P 500 (0S&P5) 4654.86 +60.24 +1.31
Nasdaq (0NDQC ) 15782.83 +291.17 +1.88
Russell 2000 (IWM) 222.67 -0.18 -0.08
IBD 50 (FFTY) 48.48 +0.78 +1.64
Last Update: 4:38 PM ET 11/29/2021

Midday Monday, President Biden said in a news conference that he doesn’t expect the U.S. to impose additional travel restrictions to slow the spread of the omicron variant. “The degree of the spread impacts on whether or not there’s a need for any travel restrictions. But I don’t anticipate that at this point,” Biden said. He added that lockdowns are off the table “for now.”

Early Tuesday, Treasury Secretary Janet Yellen and Federal Reserve chief Jerome Powell will testify before a Senate Committee in a hearing titled, “CARES Act Oversight of Treasury and the Federal Reserve: Building a Resilient Economy.”


Stock Market ETF Strategy And How To Invest


Stock Market Rally

The stock market snapped back from Friday’s sell-off, as the major stock indexes closed with sharp gains Monday.

On Friday, The Big Picture commented: “Following news over the Thanksgiving holiday that scientists are monitoring a new, fast-mutating variation of the coronavirus emerging from South Africa, stocks of all stripes gapped down at the open Friday. Judging by the half-day session’s close, the stock market expressed more caution than confidence in the short term.”

For daily stock market commentary, be sure to check out IBD’s The Big Picture.


Five Best Dow Jones Stocks To Watch Now


Dow Jones Stocks To Buy And Watch: Apple, Nike

Apple rebounded from Friday’s 3.2% loss, rallying 2.2% Monday. Shares are at the top of the buy range above a 153.27 buy point out of a cup-with-handle base, according to IBD MarketSmith chart analysis. The 5% buy zone tops out at 160.93.

Retail leader Nike is about 2% below its cup base’s 174.48 buy point after Monday’s 1.1% gain.

Dow Jones Earnings: Salesforce

Dow Jones software leader Salesforce (CRM) bullishly regained its 50-day benchmark during Monday’s 4.4% climb. Shares remain extended past a 275.32 buy point in a cup with handle despite their recent pullback.

Late Tuesday, Salesforce earnings per share are expected to fall 89% to 92 cents from a year ago. Salesforce revenue is expected to climb 25% to $6.8 billion

Stock Market Earnings: Ambarella, NetApp, Zscaler

Ambarella (AMBA), NetApp (NTAP) and Zscaler (ZS) will report their quarterly earnings results after the close Tuesday.

Chip designer Ambarella is expected to earn 49 cents per share on sales of $90.3, representing year-over-year increases of 444% and 61%, respectively. The stock found much-needed support at its 50-day line Monday.

NetApp’s earnings are expected to grow 15% to $1.21 per share year over year on revenue of $1.55 billion. NTAP shares are tracing a flat base with a 94.79 buy point. Shares are trading back above their key 50-day moving average after Monday’s 3.6% rise.

Cybersecurity leader Zscaler is expected to earn 12 cents per share on sales of $212 million. Shares closed Monday just 5% off their 52-week high following Monday’s 5.65% advance.

Stocks To Buy And Watch: Nucor, Pioneer, Pfizer, Zim

IBD Leaderboard stock Nucor has been trying to break out past a 119.42 buy point out of a cup-with-handle base, but is sharply below the entry after Monday’s 1.7% decline. Shares are about 6% below the latest entry.

Drug giant Pfizer is on the cusp of being extended past a 51.96 buy point in a cup base following a strong breakout on Friday in the wake of the newly discovered omicron variant. Shares reversed 3% lower Monday but are still above the buy point. The 5% buy zone tops out at 54.56.

Pfizer was Friday’s IBD Stock Of The Day. On Friday, vaccine partner BioNTech (BNTX) said it will take two weeks to determine whether its vaccine will be able to contend with the new variant.

Tuesday’s IBD Stock Of The Day, Pioneer Natural Resources, continues to build a flat base with a 196.74 buy point amid Monday’s 2.6% gain.

IPO Leader Zim Integrated is building a cup-with-handle base with a 60.19 buy point, according to IBD MarketSmith chart analysis. The stock advanced more than 8% Monday and is nearing the new entry.


Join IBD experts as they analyze leading stocks in the current stock market uptrend on IBD Live


EV Stocks: Li Auto, Xpeng, Lucid Motors, Rivian

Li Auto is trying to break out past a cup-with-handle base’s 34.93 buy point. The stock surged as much as 11.1% Monday before paring gains to 6.4% after the company reported quarterly earnings results ahead of the market open. Shares closed just below the entry.

The Tesla rival said it lost 6 cents a share adjusted, missing analyst targets. But revenue shot up 210% in local currency to $1.21 billion, beating the Street’s estimates. Li Auto delivered 25,116 vehicles in the third quarter. The company said fourth-quarter revenue should jump 113%-127% in local currency to $1.37 billion-$1.46 billion.

Xpeng Motors is extended past its 48.08 buy point in a choppy cup base following last week’s sharp gains. XPEV shares rose 0.5% Monday.

Lucid Motors shares traded up 6.5% Monday, more than recovering from Friday’s 1.6% decline. LCID stock remains far extended past a 28.49 buy point in a cup-with-handle base.

Hot initial public offering Rivian rose 6.8% Monday, snapping a two-day losing streak and rebounding from Friday’s 2.4% loss.

RIVN shares closed Monday about 33% off their post-IPO highs. The decline is a potential positive for investors remaining disciplined and waiting for an IPO base to form before considering a purchase. The recent weakness is the start of Rivian’s first base formation, but the last two weeks of price action weren’t very constructive given the sharp losses.

Tesla Stock

Tesla stock rallied over 5% Monday, recovering from Friday’s 3.05% skid. Shares traded as high as 1,243.49 on Nov. 4, but the stock ended Monday about 9% off its 52-week high.

TSLA shares remain sharply above a 764.55 buy point in a cup with handle, as well as earlier entries at 700.10 and 730. The chart also showed an alternate entry at 900.50.

Dow Jones Leaders: Apple, Microsoft

Among the top Dow Jones stocks, software giant Microsoft moved up 2.1% Monday, nearly erasing the entirety of Friday’s 2.4% decline.

On Oct. 18, Microsoft stock broke out past a flat base’s 305.94 buy point. The 5% buy zone topped out at 321.24, so the stock is extended.

Be sure to follow Scott Lehtonen on Twitter at @IBD_SLehtonen for more on growth stocks and the Dow Jones Industrial Average.

YOU MAY ALSO LIKE:

Top Growth Stocks To Buy And Watch

Learn How To Time The Market With IBD’s ETF Market Strategy

Find The Best Long-Term Investments With IBD Long-Term Leaders

MarketSmith: Research, Charts, Data And Coaching All In One Place

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Continue Reading

Trending